Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Clearside Biomedical ( (CLSD) ).
On September 10, 2025, Clearside Biomedical, Inc. filed a Certificate of Amendment to implement a one-for-fifteen reverse stock split and reduce its authorized common stock from 400 million to approximately 26.67 million shares, effective September 12, 2025. This strategic move, approved by stockholders and the board, will proportionately adjust stock options, restricted stock units, and warrants, with trading on a split-adjusted basis commencing on September 15, 2025, potentially impacting the company’s market positioning and shareholder value.
The most recent analyst rating on (CLSD) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.
Spark’s Take on CLSD Stock
According to Spark, TipRanks’ AI Analyst, CLSD is a Neutral.
Clearside Biomedical faces significant financial challenges, with declining revenues and negative equity being the most impactful factors. The technical analysis indicates a bearish trend, and valuation metrics are poor. While recent corporate events provide some positive aspects, the overall outlook remains risky.
To see Spark’s full report on CLSD stock, click here.
More about Clearside Biomedical
Clearside Biomedical, Inc. operates within the biotechnology industry, focusing on the development of therapies for the treatment of eye diseases. The company is known for its innovative approach in delivering drugs to the back of the eye, aiming to address unmet medical needs in ophthalmology.
Average Trading Volume: 4,521,309
Technical Sentiment Signal: Sell
Current Market Cap: $26.06M
Find detailed analytics on CLSD stock on TipRanks’ Stock Analysis page.